Clinical trials: TACE
Hepatocellular Carcinoma, Hepatoma
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially.
- Trial name
- NCT00844883
- Testing
- sorafenib, LC Bead-TACE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. In most conditions, the tumors could not be radically moved.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
- Trial name
- NCT06740370
- Testing
- TACE, Lenvatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
In this study, patients with hepatocellular carcinoma were used as the research object to explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with lipiodol embolization, and to preliminarily…
- Trial name
- NCT05053386
- Testing
- Idarubicin Hydrochloride for Injection, Epirubicin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Cancer Hospital
Primary Hepatocellular Carcinoma
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
Primary Hepatocellular Carcinoma (PHC) is one of the most common malignant tumors in the world. In men is the fifth most frequently diagnosed cancer worldwide but the second most frequent cause of cancer death.
- Trial name
- NCT01563484
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Li Chen
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.
- Trial name
- TACEHBV (NCT01102335)
- Testing
- Transcatheter arterial chemoembolization (TACE), Telbivudine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Unresectable Colorectal Liver Metastasis
Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
Colorectal cancer is the third most frequently diagnosed cancer and the third leading cause of cancer related deaths in Taiwan. Of the 10,248 new colorectal patients diagnosed each year approximately 60% will develop liver…
- Trial name
- NCT03264716
- Testing
- HepaSphere TACE (transarterial chemoembolization)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Sorafenib Chemoembolization Evaluation Controlled Trial
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients compared…
- Trial name
- SELECT (NCT01906216)
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Air Force Military Medical University, China
HCC
DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial
This is a randomized controlled trial to determine the efficacy and safety of DEB-TACE versus DEB-TACE sequential HAIC for unresectable BCLC stage C HCC
- Trial name
- NCT05788835
- Testing
- DEB-TACE and HAIC, DEB-TACE
- Where
- 16 sites in China
- Volunteers
- 220 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.
- Trial name
- NCT00357474
- Testing
- Transarterial chemoembolization, Percutaneous ethanol injection therapy
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Unresectable Hepatocellular Carcinoma, Undergoing Chemoembolization and Radioembolization
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)
The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor…
- Trial name
- TACE (NCT02093104)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Hepatocellular Carcinoma
Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System
The aim of this study is to establish a selection criteria of hepatectomy for patients with multiple hepatocellular carcinomas based on the NDR Scoring System
- Trial name
- NCT02525952
- Testing
- Hepatectomy, TACE
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation
Unresectable Colorectal Cancer, Advanced Malignancy
Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer
We plan to conduct a prospective, two-arm, open-label phase Ⅱ study to evaluate whether transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab significantly improves the efficacy and safety…
- Conditions
- Unresectable Colorectal Cancer, Advanced Malignancy, Elderly (People Aged 65 or More)
- Trial name
- NCT07209384
- Testing
- Transarterial chemoembolization
- Volunteers
- 50 people
- Sponsor
- Junpeng Wang
Hepatocellular Carcinoma
TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with pd-1 antibody immunotherapy (Sintilimab) and anti-VEGF (Bevacizumab Biosimilar) in patients with…
- Trial name
- T-Double (NCT04796025)
- Testing
- Sintilimab; Bevacizumab Biosimilar
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
HCC
Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1.
- Trial name
- NCT06285149
- Testing
- Icaritin
- Volunteers
- 80 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma
Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood vessels, but leave tumor vessels wide open.
- Trial name
- NCT02472249
- Testing
- CT perfusion, Norepinephrine intra-arteriel/hepatic
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Intrahepatic Cholangiocellular Carcinoma
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Selective Internal Radiotherapy is superior to Transarterial Chemoembolisation for the treatment of intrahepatic cholangiocellular carcinoma (CCC).
- Trial name
- NCT01798147
- Testing
- DEB TACE, SIRT
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Johannes Gutenberg University Mainz
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
The purpose of this study is to compare the survival outcomes between hepatic resection and transarterial lipiodol chemoembolization (TACE) used as the initial treatment in patients with Resectable Hepatocellular Carcinoma Beyond…
- Trial name
- NCT02138981
- Testing
- Chemoembolization and Response-Dependent Resection, Immediate Resection
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sun Yat-sen University